RVMD vs VRTX
Revolution Medicines, Inc. and Vertex Pharmaceuticals, both Healthcare
Vertex Pharmaceuticals is the larger company at $115B against $38B. Over the past year RVMD returned +336% against +32% for VRTX. The RyuScore puts VRTX ahead, 59 against 7 out of 100.
| Figure | RVMD | VRTX |
|---|---|---|
| Last close | $190 | $510 |
| Market cap | $38B | $115B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 29.7 |
| 1-year return | +336% | +32% |
| 5-year return | +542% | +168% |
| RyuScoresector-relative, 1–10 | 7/100 | 59/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Revolution Medicines, Inc.
Vertex Pharmaceuticals
Revenue of $3.3B in Q2 2026, net income $1.1B. Its largest reported line is TRIKAFTAKAFTRIO, 75% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.